Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae
暂无分享,去创建一个
A. Echaniz-Laguna | O. Lambotte | A. Masseau | S. Champiat | A. Marabelle | C. Cauquil | C. Labeyrie | G. Beaudonnet | D. Adams | J. Michot | C. Baldini | A. Laparra | N. Noel | C. Denier | A. Deleporte | S. Dehette | A. Voisin | A. Maria | P. Romano-Martin | A. Not | L. Plaçais | Maria Silva Joao | Ariane Laparra
[1] F. Ducray,et al. Central nervous system complications associated with immune checkpoint inhibitors , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.
[2] A. Cohen,et al. Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer. , 2020, JAMA oncology.
[3] P. Chanson,et al. The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study. , 2020, European journal of cancer.
[4] R. Sullivan,et al. Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum , 2020, Annals of neurology.
[5] J. Honnorat,et al. Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study , 2019, Journal of Immunotherapy for Cancer.
[6] G. Coukos,et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance , 2019, Nature Reviews Clinical Oncology.
[7] J. Dalmau,et al. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors , 2019, Nature Reviews Clinical Oncology.
[8] Kenichiro Sato,et al. Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database , 2019, Journal of Neuro-Oncology.
[9] O. Lambotte,et al. Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer. , 2019, JAMA oncology.
[10] A. Mammen,et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study , 2019, Journal of Immunotherapy for Cancer.
[11] B. Dréno,et al. Incidence and Clinical Impact of Anti-TNFα Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey. , 2019, Journal of immunotherapy.
[12] Vinay Prasad,et al. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs , 2019, JAMA network open.
[13] R. Sullivan,et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis , 2018, JAMA oncology.
[14] K. Kerr,et al. Corrections to "Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018 .
[15] U. Topaloglu,et al. Severe neurologic complications of immune checkpoint inhibitors: a single-center review , 2018, Journal of Neurology.
[16] M. Suarez‐Almazor,et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] S. Weis,et al. Fatal Necrotizing Encephalopathy after Treatment with Nivolumab for Squamous Non-Small Cell Lung Cancer: Case Report and Review of the Literature , 2018, Front. Immunol..
[18] D. Ricard,et al. Neurological toxicities associated with immune-checkpoint inhibitors , 2017, Current opinion in neurology.
[19] R. Hughes,et al. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. , 2017, The Cochrane database of systematic reviews.
[20] R. Hohlfeld,et al. Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives , 2017, Nature Reviews Neurology.
[21] X. Mariette,et al. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. , 2017, European journal of cancer.
[22] K. Kerr,et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] S. Cuzzubbo,et al. Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. , 2017, European journal of cancer.
[24] Matthieu Texier,et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination , 2016, Nature Reviews Clinical Oncology.
[25] J. Utikal,et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. , 2016, European journal of cancer.
[26] P. Chanson,et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] Y. Kong,et al. Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1 , 2014, Front. Immunol..
[28] S. Vernino,et al. Review: Progress in the management of paraneoplastic neurological disorders , 2010, Therapeutic advances in neurological disorders.
[29] Jamie L Banks,et al. Outcomes Validity and Reliability of the Modified Rankin Scale: Implications for Stroke Clinical Trials: A Literature Review and Synthesis , 2007, Stroke.
[30] I R Edwards,et al. Harmonisation in Pharmacovigilance , 1994, Drug safety.
[31] J. Larkin,et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[32] M. Bent,et al. An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes , 2005, Journal of Neurology.